News

Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae

SCHLIEREN, Switzerland--(BUSINESS WIRE)--Virometix AG, a Swiss clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced that it has successfully completed enrollment in the Phase I clinical trial of V-212, a peptide-based, serotype-independent vaccine candidate targeting Streptococcus pneumoniae infections. “Completing enrollment in this Phase I trial marks a significant milestone for V-212,”...

read more

DINAMIQS opens cGMP manufacturing facility for viral vectors

DINAMIQS, a Siegfried company (SIX: SFZN), today inaugurated its state-of-the-art cGMP manufacturing facility for viral vectors — the first of its kind in Switzerland. The new facility enables end-to-end manufacturing of viral vector gene therapies, from molecule design to aseptic drug product filling. As part of this facility, new lab...

read more

KUORI participates in Fashion for Good initiative

„If adidas, Target & Zalando can rethink plastics, what’s stopping the rest?” 👟✨ We are proud to see leading players taking real action against the massive environmental impacts of footwear production. Their commitment to testing and validating bio-based alternatives shows that disruptive innovation requires courage and collaboration. 💡 It’s inspiring to be...

read more